Mohamad Mohty, MD, PhD, Professor of Hematology at Sorbonne University and Head of the Hematology and Cellular Therapy Department at the Saint Antoine Hospital in Paris discusses some of the exciting presentations at this year’s American Society of Hematology (ASH) conference in San Diego. Specialifcally, Dr. Mohty discusses the management of hematologic diseases with cellular and immune therapies such as Chimeric antigen receptor (CAR) T cells, which have recently emerged as a novel therapeutic approach, yielding complete responses even in heavily pretreated patients with leukemia, lymphoma, and myeloma.

CAR T cells and other immune therapies represent a major paradigm shift from conventional management strategies, and there is a clear educational need to address knowledge and competence gaps among physicians regarding clinical data with CAR T cells.